Gram-Negative

Moraxella catarrhalis Infection Models

Moraxella catarrhalis is a leading cause of otitis media and respiratory infection with near-universal β-lactamase resistance. TransPharm Preclinical Solutions develops custom preclinical models to a sponsor's specifications.

Moraxella catarrhalis (M. catarrhalis) is a Gram-negative diplococcus and, alongside Streptococcus pneumoniae and non-typeable Haemophilus influenzae, one of the three leading bacterial causes of otitis media. Long dismissed as a harmless commensal of the upper respiratory tract, it is now recognized as a genuine pathogen: it causes middle-ear and sinus infection in children and is a common cause of the exacerbations that worsen chronic obstructive pulmonary disease in adults, and it can, less often, cause bacteremia and meningitis. Infants, the elderly, smokers, people with chronic lung disease, and the immunocompromised are most susceptible to colonization and subsequent infection.

Its defining feature for drug development is resistance: more than ninety percent of isolates now produce a BRO β-lactamase and are resistant to penicillins – a rise from the first resistant strain in 1977 to near-universal resistance within about two decades, among the fastest spreads of a β-lactamase ever documented in a single species.

TransPharm Preclinical Solutions can develop and validate a custom M. catarrhalis infection model to a program’s specifications.

Scientific Scope

The scientific problem in an M. catarrhalis program is that its disease is concentrated in a few respiratory sites, and the model has to reproduce the relevant one. Its principal presentations – otitis media, sinusitis, and lower-respiratory exacerbation – map directly onto infection models TransPharm Preclinical Solutions runs for other respiratory pathogens, and its rarer invasive disease onto systemic models.

Two features shape study design. First, M. catarrhalis is a human-adapted organism without a natural animal host, so establishing infection requires appropriate conditioning. Second, it frequently occurs in polymicrobial infection with S. pneumoniae and non-typeable H. influenzae, and it can shelter those organisms from β-lactams by shedding its β-lactamase in outer-membrane vesicles – so a mixed-infection design may be the more clinically faithful challenge. Because there is no off-the-shelf validated M. catarrhalis model on the current platform, the model, host, strain, and endpoints are defined together at the outset of a program.

TransPharm Preclinical Solutions maintains an on-site library of hundreds of validated pathogens and can source or validate characterized M. catarrhalis isolates, including defined β-lactamase phenotypes, to a program’s specifications.

Validated Infection Models

M. catarrhalis is validated on request rather than as a fixed model, and its principal presentations align with TransPharm Preclinical Solutions’s established platform: an otitis media model for middle-ear infection, a pulmonary model for lower-respiratory and COPD-associated disease, and bloodstream and central-nervous-system models for its rarer invasive forms. Any of these can be developed and validated for M. catarrhalis, with challenge strain, host species and strain, route of administration, comparators, dosing, and endpoints configured to the program.

The core readouts are quantitative bacterial burden (CFU) in target tissues, organs, and blood, with survival and mortality tracking where applicable, and pharmacokinetic profiling, blood chemistry, additional tissue harvests, and histopathology available as add-ons. Contact TransPharm Preclinical Solutions to scope a study design suited to your candidate.

Antimicrobial Resistance

The resistance story of M. catarrhalis is essentially the story of one enzyme family. Fewer than one in ten isolates was resistant to penicillin in the 1970s; today more than ninety percent produce a BRO β-lactamase – BRO-1 in the large majority, BRO-2 in a small minority – that hydrolyzes penicillins and makes amoxicillin and ampicillin, the drugs first reached for in otitis media, unreliable on their own.

The BRO genes appear to have been acquired from Gram-positive bacteria by horizontal transfer, which is part of why the resistance spread so quickly. The practical consequence is that treatment relies on agents that evade or overcome the enzyme: amoxicillin-clavulanate and other β-lactamase-inhibitor combinations, the extended-spectrum cephalosporins, the macrolides, and the fluoroquinolones all generally remain active. Biofilm formation in the middle ear and airway, often in mixed infection, adds a further layer of tolerance.

Because nearly every clinical isolate is a β-lactamase producer, the phenotype of the challenge strain and the choice of comparator are central to a meaningful M. catarrhalis efficacy study.